Business
NetworkNewsWire Announces Publication on Biosynthesis for Medicinal-Grade Cannabinoids
New York, New York--(Newsfile Corp. - October 26, 2017) - NetworkNewsWire ("NNW"), a multifa...
About this update from Infield Minerals Corp
[{"type":"text","content":"NetworkNewsWire Announces Publication on Biosynthesis for Medicinal-Grade CannabinoidsNew York, New York--(Newsfile Corp. - October 26, 2017) - NetworkNewsWire (\"NNW\"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a client of NNW specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids.The publication, titled, \"How Biosynthesis is Revolutionizing Cannabinoid Pharmaceuticals,\" discusses cutting-edge technology used in the manufacture of cannabinoid medicines. To view the full publication, visit: https://www.networknewswire.com/biosynthesis-revolutionizing-cannabinoid-pharmaceuticals/ \"The issue is that plant-based processes (planting, growing, harvesting, extracting and purifying) result in active ingredients at varying concentration levels with inconsistent qualities, including impurities such as pesticides. Companies interested in this approach for their products need to establish vast and high-volume marijuana greenhouse growing operations. This is a huge expense, further compounded by the complex process to produce pharmaceutical grade cannabinoids that meet the GMP requirements for FDA approval.  InMed Pharmaceuticals (CSE: IN) (OTCQB: IMLFF) has taken the inside track in the industry and has just completed the world's first-ever recorded study that successfully stitched together several key components in the drug development continuum for cannabinoid therapies.\"Following this success, InMed is scaling its manufacturing process and pursuing research into other medical conditions by leveraging its know-how in cannabinoid drug development. Because biosynthesized cannabinoids are identical to those found in nature, they have potentially fewer adverse events associated with varying drug structures and may confer better efficacy. Biosynthesis also avoids several of the drawbacks associated with growing marijuana, including elimination of pesticides that can be toxic to people and harmful to the environment.\"About InMed InMed is a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems. InMed conducts research, discove...